Get started
Author

Letuan Phan

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial
2022 · Yann-Alexandre Vano, Réza Elaidi, et al. · The Lancet Oncology · 143
Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
2023 · A Daban, C Gonnin, et al. · OncoImmunology · 43
PDF
Plasma CD27, a Surrogate of the Intratumoral CD27–CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma
2022 · Nadine Benhamouda, Ikuan Sam, et al. · Clinical Cancer Research · 41
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer
2023 · Stéphane Oudard, Raffaele Ratta, et al. · JAMA Oncology · 24
Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis
2020 · Reza ELAIDI, Letuan PHAN, et al. · Cancers · 21
PDF
Preexisting autoantibodies as predictor of immune-related adverse events for advanced solid tumors treated with immune checkpoint inhibitors.
2022 · Arthur Daban, Cecile Gonnin, et al. · Journal of Clinical Oncology · 13
Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
2022 · Yann‐Alexandre Vano, Letuan Phan, et al. · International Journal of Cancer · 11
PDF
Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study
2018 · Guillaume Cartron, Rémi Letestu, et al. · Haematologica · 9
PDF
Beyond handcrafted radiomics in oncologic imaging: Innovations in deep, explainable, multi-site and multi-omics radiomics approaches
2026 · Jules Dupont, Fiona Frau, et al. · Diagnostic and Interventional Imaging · 6
Overall survival (OS) and efficacy results of second-line treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) treated in the randomized phase II BIONIKK trial.
2023 · Yann-Alexandre Vano, Letuan Phan, et al. · Journal of Clinical Oncology · 3
Optimal molecular selection to benefit from nivolumab–ipilimumab in clear-cell renal cell carcinoma
2022 · Yann-Alexandre Vano, Réza Elaidi, et al. · The Lancet Oncology · 3
Radiological, Radiomics, and Metastatic Patterns Associated with Targetable Oncogenic Drivers on CT-Scan of Newly Diagnosed NSCLC Patients: A Comprehensive Radiogenomics Review
2026 · Letuan Phan, Sophie Cousin, et al. · Cancers · 2
Supplementary Figure from Plasma CD27, a Surrogate of the Intratumoral CD27–CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma
2023 · Nadine Benhamouda, Ikuan Sam, et al. · 1
1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial
2022 · M. Meylan, C-M. Sun, et al. · Annals of Oncology · 1
PDF
Serial circulating tumour DNA monitoring in first-line advanced NSCLC (COPE): a randomized, two-arm non-comparative phase II trial
2026 · Candice Francheska B. Tambaoan, Letuan Phan, et al. · Clinical Cancer Research
Estimating Metastatic Disease Heterogeneity Using Radiomics-based Lesion Clustering and Heterogeneity Index - Application in Lung Adenocarcinoma Patients and Correlations With Patient Outcomes
2026 · Letuan Phan, Lou Andrea Sitruk, et al. · Journal of Imaging Informatics in Medicine
Serial ctDNA genomic profiling integrated with a networked molecular tumor board in first-line advanced NSCLC: The COPE randomized phase II trial.
2026 · Antoine Italiano, Candice Francheska Tambaoan, et al. · Journal of Clinical Oncology
Correlating and Combing Intra- and Inter-Metastases Radiophenotypic and Molecular Heterogeneities (Metastatic lung cancers)
2025 · Phan, Letuan · Fondation Maison des sciences de l'homme
ctDNA features of acquired resistance to immunotherapy in advanced NSCLC.
2025 · Sofiane Taleb, Letuan Phan, et al. · Journal of Clinical Oncology
PDF
1375P Sequential ctDNA profiling in patients with advanced non-small cell lung cancer: An interim analysis of the COPE randomized study
2024 · A. Italiano, L. Phan, et al. · Annals of Oncology
PDF
Supplementary Data from Plasma CD27, a Surrogate of the Intratumoral CD27–CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma
2023 · Nadine Benhamouda, Ikuan Sam, et al.
Supplementary Table from Plasma CD27, a Surrogate of the Intratumoral CD27–CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma
2023 · Nadine Benhamouda, Ikuan Sam, et al.
Data from Plasma CD27, a Surrogate of the Intratumoral CD27–CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma
2023 · Nadine Benhamouda, Ikuan Sam, et al.
Supplementary Data from Plasma CD27, a Surrogate of the Intratumoral CD27–CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma
2023 · Nadine Benhamouda, Ikuan Sam, et al.
Supplementary Data from Plasma CD27, a Surrogate of the Intratumoral CD27–CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma
2023 · Nadine Benhamouda, Ikuan Sam, et al.
Works count: 31
Citation count: 321
H-index: 8
I10-index: 7
Year
Topic
Type